0H19 Stock Chart & Stats
kr15.10
kr0.00(0.00%)
At close: 4:00 PM EDT
kr15.10
kr0.00(0.00%)
Day’s Range― - ―
52-Week Rangekr14.42 - kr38.25
Previous CloseN/A
Volume0.00
Average Volume (3M)780.00
Market Cap
kr467.25M
Enterprise Valuekr576.03
Total Cash (Recent Filing)kr276.90M
Total Debt (Recent Filing)kr9.90M
Price to Earnings (P/E)―
Beta-0.40
Next Earnings
Oct 22, 2026EPS Estimate
-2.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.81
Shares Outstanding35,127,056
10 Day Avg. Volume107
30 Day Avg. Volume780
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.12
Price to Sales (P/S)40.09
P/FCF Ratio6.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-9.03
Revenue Forecast (FY)kr26.00M
Bulls Say, Bears Say
Bulls Say
Long-lived IP And Diversified PipelineLong patent protection can support durable commercial value if programs succeed. The pipeline across allergy, OUD, vaccines and GLP-1 also reduces reliance on a single product and creates multiple potential licensing or launch opportunities.
BARDA-backed OX390 DevelopmentExternal BARDA financing lowers Orexo’s direct development burden and helps preserve resources while OX390 advances. Positive preclinical data and non-dilutive support improve the program’s ability to reach later milestones without relying entirely on internal cash.
Improved Leverage And Available CashThe improved solvency profile provides more flexibility than in prior periods of high leverage or thin equity. Cash reserves can fund operations and selected development work, although continued losses mean this financial buffer must be managed carefully.
Bears Say
Deep Losses And Severe Revenue ContractionWeak revenue and negative gross profit indicate that the current commercial base is not covering the cost structure. Sustained losses limit internal funding for the pipeline and make future performance dependent on successful launches, partnerships or financing.
Unproven Cash-flow DurabilityThe sharp quarterly cash outflow can materially reduce the company’s runway if operating conditions persist. Although TTM cash flow had recently turned positive, ongoing net losses and volatile cash generation make that improvement unreliable as a durable funding source.
DOJ Uncertainty And Future Funding NeedsAn unresolved DOJ matter creates uncertainty around potential payments, legal costs and financing access. At the same time, substantial OX640 spending may arrive before partners assume costs, increasing the risk of dilution, delayed development or reduced strategic flexibility.
Orexo AB News
0H19 FAQ
What was Orexo AB’s price range in the past 12 months?
Orexo AB lowest share price was kr14.42 and its highest was kr38.25 in the past 12 months.
What is Orexo AB’s market cap?
Orexo AB’s market cap is kr467.25M.
When is Orexo AB’s upcoming earnings report date?
Orexo AB’s upcoming earnings report date is Oct 22, 2026 which is in 52 days.
How were Orexo AB’s earnings last quarter?
Orexo AB released its earnings results on Jul 16, 2026. The company reported -kr2.2 earnings per share for the quarter, missing the consensus estimate of -kr1.6 by -kr0.6.
Is Orexo AB overvalued?
According to Wall Street analysts Orexo AB’s price is currently Overvalued.
Does Orexo AB pay dividends?
Orexo AB does not currently pay dividends.
What is Orexo AB’s EPS estimate?
Orexo AB’s EPS estimate is -2.1.
How many shares outstanding does Orexo AB have?
Orexo AB has 35,127,056 shares outstanding.
What happened to Orexo AB’s price movement after its last earnings report?
Orexo AB reported an EPS of -kr2.2 in its last earnings report, missing expectations of -kr1.6. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Orexo AB?
Currently, no hedge funds are holding shares in GB:0H19
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis. Its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
0H19 Company Deck
0H19 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed picture: strong scientific and programmatic progress (positive in vivo data for OX390, Izipry filing on track, OX640 progression, BARDA funding, and business development momentum) and valuable strategic assets (long IP life, AmorphOX platform interest). However, short-term financials are challenged by material one-off costs (GAIA settlement), ongoing DOJ uncertainty, substantial quarterly cash burn and low revenues. Management has clear plans to reduce run-rate OpEx and pursue partnerships and financing, but timing and DOJ resolution are key near-term risks.View all GB:0H19 earnings summariesTechnical Analysis
Swedish Orphan Biovitrum AB
―
Camurus AB
―
AlzeCure Pharma AB
―
IRLAB Therapeutics AB Class A
―
Xspray Pharma AB
―